Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchSpironolactoneSpironolactone (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
Spironolactone for COVID-19
12 studies from 107 scientists
28,019 patients in 9 countries
Statistically significant lower risk for mortality, progression, and recovery.
11 studies from 10 independent teams in 8 countries show statistically significant improvements.
COVID-19 Spironolactone studies. Mar 2024. c19early.org
0 0.5 1 1.5+ All studies 31% With exclusions 36% Mortality 30% Hospitalization 52% Recovery 49% Cases 50% Viral clearance 46% RCTs 44% Prophylaxis 13% Early 77% Late 42% Favorsspironolactone Favorscontrol
Mar 16
Covid Analysis Spironolactone for COVID-19: real-time meta analysis of 12 studies
Statistically significant lower risk is seen for mortality, progression, and recovery. 11 studies from 10 independent teams in 8 countries show statistically significant improvements. Meta analysis using the most serious outcome reported ..
Dec 18
2023
Mehrizi et al., Frontiers in Public Health, doi:10.3389/fpubh.2023.1280434 Drug prescription patterns and their association with mortality and hospitalization duration in COVID-19 patients: insights from big data
32% lower mortality (p<0.0001). Retrospective study of 917,198 hospitalized COVID-19 cases covered by the Iran Health Insurance Organization over 26 months showing that antithrombotics, corticosteroids, and antivirals reduced mortality while diuretics, antibiotics, and..
Mar 2
2023
Cousins et al., medRxiv, doi:10.1101/2023.02.28.23286515 Association between spironolactone use and COVID-19 outcomes in population-scale claims data: a retrospective cohort study
18% lower mortality (p=0.004) and 17% lower ventilation (p<0.0001). PSM retrospective 898,303 hospitalized COVID-19 patients in the USA, 16,324 on spironolactone, showing lower mortality and ventilation with spironolactone use.
Jul 6
2022
Cousins et al., Cell Reports Methods, doi:10.1016/j.crmeth.2023.100503 (date from preprint) Integrative analysis of functional genomic screening and clinical data identifies a protective role for spironolactone in severe COVID-19
81% lower ventilation (p=0.006) and 66% lower ICU admission (p=0.002). PSM retrospective 64,349 COVID-19 patients in the USA, showing spironolactone associated with lower ICU admission. Authors also present In Vitro research showing dose-dependent inhibition in a human lung epithelial cell line.
Jul 2
2022
Wadhwa et al., medRxiv, doi:10.1101/2022.07.01.22277163 Phase 2 randomised placebo-controlled trial of spironolactone and dexamethasone versus dexamethasone in COVID-19 hospitalised patients in Delhi
72% lower progression (p=0.03), 49% higher hospital discharge (p=0.05), and 18% faster recovery (p=0.06). RCT 120 hospitalized patients in India, 74 treated with spironolactone and dexamethasone, and 46 with dexamethasone, showing lower progression with treatment. Spironolactone 50mg once daily day 1, 25mg once daily until day 21.
Mar 29
2022
MacFadden et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156 Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications
7% fewer cases (p=0.008). Retrospective 26,121 cases and 2,369,020 controls ≥65yo in Canada, showing lower cases with chronic use of spironolactone.
Feb 7
2022
Abbasi et al., Journal of the Endocrine Society, doi:10.1210/jendso/bvac017 A Randomized Trial of Sitagliptin and Spironolactone With Combination Therapy in Hospitalized Adults With COVID-19
55% lower mortality (p=0.1), 34% lower ventilation (p=0.36), 19% lower ICU admission (p=0.67), and 47% improved recovery (p<0.0001). RCT including 51 spironolactone patients and 87 control patients in Iran, showing improved recovery with spironolactone, sitagliptin, and the combination of both.
Jan 21
2022
Davarpanah et al., medRxiv, doi:10.1101/2022.01.21.22269322 Combination of Spironolactone and Sitagliptin Improves Clinical Outcomes of Outpatients with COVID-19: An Observational Study
78% lower hospitalization (p=0.0008) and 64% faster recovery (p=0.0001). Prospective study of 206 outpatients in Iran, 103 treated with spironolactone and sitagliptin, showing lower hospitalization and faster recovery with treatment. spironolactone 100mg and sitagliptin 100mg daily.
Oct 13
2021
Ersoy et al., Aydin Sağlik Dergi̇si̇, doi:10.17932/IAU.ASD.2015.007/asd_v07i3002 Assessment Of The Efficacy Of Spironolactone For COVID-19 ARDS Patients
46% lower mortality (p=0.002). Retrospective 30 COVID-19 ARDS ICU patients and 30 control patients, showing lower mortality with treatment.
Feb 23
2021
Jeon et al., Frontiers in Medicine, doi:10.3389/fmed.2021.629176 Effect of Spironolactone on COVID-19 in Patients With Underlying Liver Cirrhosis: A Nationwide Case-Control Study in South Korea
77% fewer cases (p=0.005). Retrospective 6,462 liver cirrhosis patients in South Korea, with 67 COVID+ cases, showing significantly lower cases with spironolactone treatment. Death and ICU results per group are not provided.
Dec 3
2020
Mareev et al., Кардиология, doi:10.18087/cardio.2020.11.n1440 Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)
11% improved recovery (p=0.47), 8% shorter hospitalization (p=0.35), and 87% improved viral clearance (p=0.08). Prospective 103 PCR+ patients in Russia, 33 treated with bromexhine+spironolactone, showing lower PCR+ at day 10 or hospitalization >10 days with treatment. Bromhexine 8mg 4 times daily, spironolactone 25-50 mg/day for 10 days.
Oct 6
2020
Cadegiani et al., medRxiv, doi:10.1101/2020.10.05.20206870 An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial
77% faster recovery (p=0.006) and 38% faster viral clearance (p=0.02). Prospective study of 270 female COVID-19 patients in Brazil, 75 with hyperandrogenism, of which 8 were on spironolactone. Results suggest that HA patients may be at increased risk, and that spironolactone use may reduce the risk compared ..
May 7
2020
Holt et al., Journal of Hypertension, doi:10.1097/hjh.0000000000002515 Influence of inhibitors of the renin–angiotensin system on risk of acute respiratory distress syndrome in Danish hospitalized COVID-19 patients
129% higher combined mortality/ICU admission (p=0.0007). Retrospective 689 hospitalized COVID-19 patients in Denmark, showing higher risk of ICU/death with spironolactone use in unadjusted results subject to confounding by indication.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit